Tandem Diabetes Care INC Form 4 insider transactions

Tandem Diabetes Care Inc.'s Chief Technology Officer, Rick Carpenter, reported the vesting of restricted stock units and subsequent share withholding for tax obligations on June 16, 2025.

Mark Novara, EVP & Chief Commercial Officer of Tandem Diabetes Care Inc., reported the vesting and subsequent tax-related withholding of restricted stock units.

Tandem Diabetes Care Inc. Director Myoungil Cha acquired 1,749 shares of common stock on June 16, 2025, through the vesting of restricted stock units.

Joao Paulo Falcao Malagueira, a Director at Tandem Diabetes Care Inc., acquired 1,749 shares of common stock through the exercise of restricted stock units on June 16, 2025.

Tandem Diabetes Care Inc.'s Executive Vice President and Chief Financial Officer, Leigh Vosseller, was granted 31,486 Performance Stock Units and 31,488 Restricted Stock Units on May 30, 2025, as part of the company's long-term incentive plan.

Tandem Diabetes Care's Executive Vice President and Chief Commercial Officer, Mark Novara, was granted substantial performance and restricted stock units as part of the company's long-term incentive plan.

Jean-Claude Kyrillos, Executive Vice President and Chief Operating Officer of Tandem Diabetes Care Inc., has been granted performance stock units and restricted stock units totaling over 24,000 shares under the company's long-term incentive plan.

Tandem Diabetes Care's EVP & Chief Administrative Officer, Susan Morrison, was granted 20,768 Performance Stock Units and 20,768 Restricted Stock Units under the company's 2023 Long-Term Incentive Plan.

Shannon Marie Hansen, Executive Vice President and Chief Legal Officer of Tandem Diabetes Care Inc., reported the acquisition of 23,000 Performance Stock Units and 23,002 Restricted Stock Units on May 30, 2025, under the company's long-term incentive plan.

Tandem Diabetes Care Inc.'s President and CEO, John F. Sheridan, was granted substantial performance and restricted stock units on May 30, 2025, aligning executive compensation with future company performance and shareholder value.

Tandem Diabetes Care's EVP, Chief Strategy Officer, Elizabeth Anne Gasser, was granted 23,000 Performance Stock Units and 23,002 Restricted Stock Units as part of the company's 2023 Long-Term Incentive Plan.

Tandem Diabetes Care's Chief Technology Officer, Rick Carpenter, was awarded 19,316 Performance Stock Units and 19,317 Restricted Stock Units on May 30, 2025, as part of the company's long-term incentive plan.

Dick Allen, a Director at Tandem Diabetes Care Inc. (TNDM), reported gifting 1,000 shares of common stock valued at $19.88 per share on June 2, 2025.

Elizabeth Anne Gasser, EVP and Chief Strategy Officer of Tandem Diabetes Care Inc., transferred 11,200 shares of common stock from her direct holdings to The Gasser Family Trust on May 29, 2025.

Rajwant Sodhi, a Director at Tandem Diabetes Care Inc. (TNDM), reported the exercise of restricted stock units into common stock and the grant of new restricted stock units, increasing their direct beneficial ownership.

Kathleen McGroddy-Goetz, a Director at Tandem Diabetes Care Inc., converted 4,387 restricted stock units into common stock and was granted an additional 8,759 restricted stock units.

Tandem Diabetes Care Inc. Director Myoungil Cha reported the acquisition of 4,387 common shares upon RSU vesting and the grant of 8,759 new restricted stock units.

Rebecca B. Robertson, a Director at Tandem Diabetes Care Inc., reported an increase in her direct common stock ownership following the conversion of restricted stock units and the grant of new equity awards.

Peyton R. Howell, a Director at Tandem Diabetes Care Inc., reported the acquisition of 4,387 shares of common stock following the vesting of restricted stock units and received a new grant of 8,759 restricted stock units.

Tandem Diabetes Care Inc. Director Christopher J. Twomey reported the acquisition of 4,387 shares of common stock through the vesting of restricted stock units and the grant of 8,759 new restricted stock units.

Tandem Diabetes Care Inc. Director Joao Paulo Falcao Malagueira exercised 4,387 restricted stock units and was granted 8,759 new restricted stock units.

Tandem Diabetes Care Inc. Director Dick Allen reported the acquisition of common stock through RSU vesting and a new grant of restricted stock units, increasing his direct and indirect holdings.

Shannon Marie Hansen, EVP & Chief Legal Officer of Tandem Diabetes Care, reports the vesting of restricted stock units and subsequent withholding of shares for tax obligations.

EVP & Chief Commercial Officer of Tandem Diabetes Care, Mark Novara, reports acquisition and disposal of company stock, including shares acquired through an employee stock purchase plan and shares withheld for tax obligations.

EVP and Chief Admin. Officer of Tandem Diabetes Care, Susan Morrison, reports acquisition and disposal of company stock and restricted stock units.

EVP, Chief Strategy Officer of Tandem Diabetes Care, Elizabeth Gasser, reports acquisition and disposal of company stock and restricted stock units.

Rick Carpenter, Chief Technology Officer of Tandem Diabetes Care, reports acquisition and disposal of company stock and restricted stock units.

John F. Sheridan, President and CEO of Tandem Diabetes Care, reports acquisition and disposal of company stock and restricted stock units on May 15, 2025.

Jean-Claude Kyrillos, EVP & Chief Operating Officer of Tandem Diabetes Care, acquired 171 shares of common stock through the company's Employee Stock Purchase Plan.

EVP and CFO of Tandem Diabetes Care, Leigh Vosseller, reports acquisition and disposal of company stock and restricted stock units (RSUs) on May 15, 2025.